Patents by Inventor Glenn P. Vonk
Glenn P. Vonk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220146514Abstract: Some embodiments provided herein relate to combined assays. In some embodiments, an assay for identifying influenza type A or influenza type B is combined with an assay for determining the sensitivity of an influenza neuraminidase to an antiviral drug.Type: ApplicationFiled: November 16, 2021Publication date: May 12, 2022Inventors: Robert Campbell, Kevin G. Dolan, Eric Fallows, Randal A. Hoke, Ross Jacobson, J. Bruce Pitner, Glenn P. Vonk, Rajashaker Kache, Upma Gulati, Herman D. Himel, IV, Rosemary B. Evans-Storms
-
Patent number: 11209433Abstract: Some embodiments provided herein relate to combined assays. In some embodiments, an assay for identifying influenza type A or influenza type B is combined with an assay for determining the sensitivity of an influenza neuraminidase to an antiviral drug.Type: GrantFiled: April 15, 2019Date of Patent: December 28, 2021Assignee: Becton, Dickinson and CompanyInventors: Robert Campbell, Kevin G. Dolan, Eric Fallows, Randal A. Hoke, Ross Jacobson, J. Bruce Pitner, Glenn P. Vonk, Rajashaker Kache, Upma Gulati, Herman D. Himel, IV, Rosemary B. Evans-Storms
-
Publication number: 20190339272Abstract: Some embodiments provided herein relate to combined assays. In some embodiments, an assay for identifying influenza type A or influenza type B is combined with an assay for determining the sensitivity of an influenza neuraminidase to an antiviral drug.Type: ApplicationFiled: April 15, 2019Publication date: November 7, 2019Inventors: Robert Campbell, Kevin G. Dolan, Eric Fallows, Randal A. Hoke, Ross Jacobson, J. Bruce Pitner, Glenn P. Vonk, Rajashaker Kache, Upma Gulati, Herman D. Himel, IV, Rosemary B. Evans-Storms
-
Patent number: 10317404Abstract: Some embodiments provided herein relate to combined assays. In some embodiments, an assay for identifying influenza type A or influenza type B is combined with an assay for determining the sensitivity of an influenza neuraminidase to an antiviral drug.Type: GrantFiled: April 1, 2014Date of Patent: June 11, 2019Assignee: BECTON, DICKINSON AND COMPANYInventors: Robert Campbell, Kevin G. Dolan, Eric Fallows, Randal A. Hoke, Ross Jacobson, J. Bruce Pitner, Glenn P. Vonk, Rajashaker Kache, Upma Gulati, Herman Himel, Rosemary B. Evans-Storms
-
Publication number: 20160041167Abstract: Some embodiments provided herein relate to combined assays. In some embodiments, an assay for identifying influenza type A or influenza type B is combined with an assay for determining the sensitivity of an influenza neuraminidase to an antiviral drug.Type: ApplicationFiled: April 1, 2014Publication date: February 11, 2016Inventors: Robert Campbell, Kevin G. Dolan, Eric Fallows, Randall A. Hoke, Ross Jacobson, J. Bruce Pinter, Glenn P. Vonk, Rajashaker Kache, Upma Gulati, Herman Himel, Rosemary B. Evans-Storms
-
Publication number: 20150056634Abstract: Methods and compositions for preparing dry formulations of Glucose Binding Proteins (GBPs) are disclosed. The GBPs may be stored as a dry formulation without significant loss of activity. After reconstitution, the GBPs may be used to determine the glucose concentration of a sample.Type: ApplicationFiled: March 28, 2013Publication date: February 26, 2015Applicant: Becton, Dickinson and CompanyInventors: Matthew S. Ferriter, Javier Alarcon, Glenn P. Vonk, Melody M.H. Kuroda, Mark Foster Sistare, Brandi Marie Ford
-
Patent number: 7369919Abstract: A system comprising a medication tray (10) and a docking station (20) for facilitating effective self-management of medication treatment by patients is provided. The medication tray (10) accepts medication filled containers (30) and mates with the docking station (20). The medication tray (10) receives prescription data at the time the medication tray (10) accepts the medication filled containers (30), which is then downloaded to the docking station (20). The docking station (20) monitors and reports to third parties, via a network (160), a patient's compliance with various medication treatment regimens. Medication containers (30) are provided with low bit tags (35) that provide container presence information to the docking station (20). The docking station (20) provides visual and/or audio signals regarding prescription data to a patient. The docking station (20) can query patients and appliances regarding patient's medication usage and health status.Type: GrantFiled: November 26, 2002Date of Patent: May 6, 2008Inventors: Glenn P. Vonk, Richard C. Rumbaugh, Colleen Ryan
-
Patent number: 6077669Abstract: The present invention relates to kits and methods for conducting fluorescence based detection assays. The kits are configured in a manner to perform the method so as to reduce or eliminate interfering fluorescence signal.Type: GrantFiled: November 4, 1997Date of Patent: June 20, 2000Assignee: Becton Dickinson and CompanyInventors: Michael C. Little, Glenn P. Vonk
-
Patent number: 6054279Abstract: Single-stranded signal primers are modified by linkage to two dyes which form a donor/acceptor dye pair. The two dyes are positioned in sufficiently close spatial proximity on the signal primer that the fluorescence of the first dye is quenched by the second dye. The signal primer may further comprise a restriction endonuclease recognition site (RERS) between the two dyes. As the signal primer is initially single-stranded and remains single-stranded in the absence of target, the restriction endonuclease recognition site is not cleavable or nickable by the restriction endonuclease. In the presence of target, however, signal primer and the restriction endonuclease recognition site are rendered double-stranded and cleavable or nickable by the restriction endonuclease. Cleavage or nicking separates the two dyes and a change in fluorescence due to decreased quenching is detected as an indication of the presence of the target sequence or of target sequence amplification.Type: GrantFiled: July 20, 1998Date of Patent: April 25, 2000Assignee: Becton Dickinson and CompanyInventors: James G. Nadeau, J. Bruce Pitner, James L. Schram, C. Preston Linn, Glenn P. Vonk, G. Terrance Walker
-
Patent number: 5919630Abstract: Single-stranded signal primers are modified by linkage to two dyes which form a donor/acceptor dye pair. The two dyes are positioned in sufficiently close spatial proximity on the signal primer that the fluorescence of the first dye is quenched by the second dye. The signal primer may further comprise a restriction endonuclease recognition site (RERS) between the two dyes. As the signal primer is initially single-stranded and remains single-stranded in the absence of target, the restriction endonuclease recognition site is not cleavable or nickable by the restriction endonuclease. In the presence of target, however, signal primer and the restriction endonuclease recognition site are rendered double-stranded and cleavable or nickable by the restriction endonuclease. Cleavage or nicking separates the two dyes and a change in fluorescence due to decreased quenching is detected as an indication of the presence of the target sequence or of target sequence amplification.Type: GrantFiled: November 4, 1998Date of Patent: July 6, 1999Assignee: Becton, Dickinson and CompanyInventors: James G. Nadeau, J. Bruce Pitner, James L. Schram, C. Preston Linn, Glenn P. Vonk, G. Terrance Walker
-
Patent number: 5888739Abstract: G-quartet structures have been found to be useful in fluorescence assays to detect a selected nucleic acid sequence. When oligonucleotides containing these structures are labeled with a donor fluorophore and an acceptor dye, the folding or interaction of the oligonucleotides in the G-quartet structure brings the donor-acceptor pair into close proximity, allowing an interaction between the two labels which results in quenching of donor fluorescence or a change in other fluorescence properties which are the result of the interaction of two dyes in close proximity. The G-quartet structure unfolds or is otherwise disrupted upon hybridization to its complementary sequence, increasing the distance between the two dye labels. This results in decreased donor quenching or a change in another proximity-related fluorescence parameter.Type: GrantFiled: September 9, 1997Date of Patent: March 30, 1999Assignee: Becton, Dickinson and CompanyInventors: J. Bruce Pitner, James G. Nadeau, Glenn P. Vonk
-
Patent number: 5846726Abstract: Single-stranded signal primers are modified by linkage to two dyes which form a donor/acceptor dye pair. The two dyes are positioned in sufficiently close spatial proximity on the signal primer that the fluorescence of the first dye is quenched by the second dye. The signal primer may further comprise a restriction endonuclease recognition site (RERS) between the two dyes. As the signal primer is initially single-stranded and remains single-stranded in the absence of target, the restriction endonuclease recognition site is not cleavable or nickable by the restriction endonuclease. In the presence of target, however, signal primer and the restriction endonuclease recognition site are rendered double-stranded and cleavable or nickable by the restriction endonuclease. Cleavage or nicking separates the two dyes and a change in fluorescence due to decreased quenching is detected as an indication of the presence of the target sequence or of target sequence amplification.Type: GrantFiled: May 13, 1997Date of Patent: December 8, 1998Assignee: Becton, Dickinson and CompanyInventors: James G. Nadeau, J. Bruce Pitner, James L. Schram, C. Preston Linn, Glenn P. Vonk, G. Terrance Walker
-
Patent number: 5691145Abstract: Oligonucleotides which form G-quartet structures have been found to be useful in fluorescence assays to detect a selected nucleic acid sequence. When one end of the oligonucleotide is labeled with a donor fluorophore and the other end is labeled with an acceptor dye, the folding of the molecule in the G-quartet structure brings the donor-acceptor pair into close proximity, allowing an interaction between the two labels which results in quenching of donor fluorescence or a change in other fluorescence properties which are the result of the interaction of two dyes in close proximity. The G-quartet structure unfolds upon hybridization to its complementary sequence, increasing the distance between the two dye labels. This results in decreased donor quenching or a change in another proximity-related fluorescence parameter. The associated increase in donor fluorescence intensity or the change in another fluorescence parameter may be monitored as an indication of the presence of a selected nucleic acid sequence.Type: GrantFiled: August 27, 1996Date of Patent: November 25, 1997Assignee: Becton, Dickinson and CompanyInventors: J. Bruce Pitner, Glenn P. Vonk, James G. Nadeau
-
Patent number: 5650275Abstract: The invention relates to methods of using spectroscopically detectable labeled receptor molecules to determine the presence or absence of a target compound in a sample. In one embodiment, spectroscopically detectable labeled nucleic acid ligands are used to determine the presence or absence of biological targets of interest in biological samples.Type: GrantFiled: July 18, 1994Date of Patent: July 22, 1997Inventors: J. Bruce Pitner, Douglas P. Malinowski, Glenn P. Vonk, Larry Gold
-
Patent number: 5641629Abstract: The present invention relates to methods of using spectroscopically detectable labeled receptor molecules to determine the presence or absence of a target compound in a sample. In one embodiment, spectroscopically detectable labeled nucleic acid ligands are used to determine the presence or absence of biological targets of interest in biological samples.Type: GrantFiled: January 20, 1995Date of Patent: June 24, 1997Inventors: James B. Pitner, Douglas P. Malinowski, Glenn P. Vonk, Larry Gold
-
Patent number: 5370994Abstract: A method for detecting urea in a liquid sample in which urease is adsorbed on a solid support such as a membrane and contacted with a solution suspected of containing urea, a pH-dependent reducing agent and a tetrazolium salt. When urea is present in the solution, the adsorbed urease converts it to ammonia, thus raising the pH and causing the pH-dependent reducing agent to reduce the tetrazolium salt to an insoluble colored formazan. The formazan precipitates as a detectable spot on the solid support, indicating the presence of urea in the liquid sample.Type: GrantFiled: December 10, 1993Date of Patent: December 6, 1994Assignee: Becton, Dickinson and CompanyInventors: Thomas N. Stewart, Glenn P. Vonk, James P. Mapes
-
Patent number: 5328831Abstract: A substrate composition for use in a solid phase enzyme assay for urease or in a solid phase enzyme immunoassay which includes urease as a label. The substrate composition includes a compound converted by urease to ammonia and a pH dependent reducing agent which reduces a tetrazolium salt when the pH of the medium has been raised by the ammonia produced. The tetrazolium salt may optionally be included in the substrate composition. Reduction of the tetrazolium salt produces a colored insoluble formazan which precipitates on the solid phase as an indication of the presence of urease.Type: GrantFiled: March 16, 1992Date of Patent: July 12, 1994Assignee: Becton, Dickinson and CompanyInventors: Thomas N. Stewart, Glenn P. Vonk, James P. Mapes
-
Patent number: 5314801Abstract: The invention provides methods and nucleic acid probes for deleting, amplifying, and isolating sequences of Mycobacterium avium, Mycobacterium intracellulare, and Mycobacterium paratuberculosis.Type: GrantFiled: November 6, 1992Date of Patent: May 24, 1994Assignee: Becton, Dickinson and CompanyInventors: Colleen M. Nycz, James L. Schram, Daryl D. Shank, Glenn P. Vonk
-
Patent number: 5185127Abstract: An assay device includes a filter stack in an enclosure having a base portion and a lid. The filter stack has a hydrophilic membrane having a binder for an analyte thereon, a hydrophobic membrane under the hydrophilic membrane and a pad of absorbent material under the hydrophobic membrane. The lid includes an upwardly extending rim which defines a recess having an insert therein. Aligned openings in the lid and insert provide access to the hydrophilic membrane. The hydrophobic membrane is impervious to the passage of an aqueous liquid until wetted by a wetting agent. The invention includes a kit of materials for performing an assay for an analyte which includes the device.Type: GrantFiled: March 24, 1992Date of Patent: February 9, 1993Assignee: Becton, Dickinson and CompanyInventor: Glenn P. Vonk
-
Patent number: 5139934Abstract: A method for enzyme immunoassay of a ligand includes urease as a label. A bound fraction of ligand and antiligand conjugated to urease is formed on a solid support. The urease component of the bound fraction is contacted with a substrate composition for urease which includes a compound converted to ammonia by the urease, a tetrazolium salt and a pH dependent reducing agent which reduces the tetrazolium salt when the pH of the assay medium has been raised by the ammonia. The tetrazolium salt is reduced to a colored insoluble formazan which precipitates as a detectable spot on the support. The invention includes the substrate composition and a kit of materials for performing the assay.Type: GrantFiled: May 25, 1990Date of Patent: August 18, 1992Assignee: Becton, Dickinson and CompanyInventors: Thomas N. Stewart, Glenn P. Vonk, James P. Mapes